Find a Clinical Trial
Filter
AN2 EBO301 MAC Study
Mycobacterial disease
All genders
18+
Recruiting now
Department of Medicine, Division of Geographic Medicine + Infectious Diseases
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center